Aligos Therapeutics, Inc. (ALGS) stock
Close on Nov 11, 2026Market cap $26.98MP/E –Yield –
Aligos Therapeutics, Inc. grew revenue 122.2% to $5.83M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $26.98M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $26.98M
- P/E ratio
- –
- Price to sales
- 4.63
- Price to book
- 2.39
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $5.83M
- Net income
- -$66.29M
- EPS, diluted
- -$2.45
- Book value per share
- $1.08
- Diluted shares
- 10M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $2.57
- Open
- $2.79
- Day's range
- $2.02 – $2.81
- Volume
- 284,204
- Average volume (20 days)
- 60,750
- Beta (5 years)
- 1.50
- 52-week range
- $2.02 – $13.69
- RSI (14 days)
- 18.9
- Volatility (1 year)
- 96.9%
- Relative volume
- 3.11×
- WACC
- 12.4%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALGS | S&P 500 | Difference | ALGS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -59.6% | -2.4% | −57.1 pts | ||
| 3 months | -70.3% | -1.2% | −69.2 pts | ||
| Year to date | -76.8% | +12.3% | −89.1 pts | ||
| 1 year | -67.7% | +12.4% | −80.1 pts | ||
| 3 years | -87.6% | +78.8% | −166.4 pts | -50.2% | +21.4% |
| 5 years | -99.5% | +75.2% | −174.7 pts | -65.1% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aligos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- Results
- Results
About Aligos Therapeutics
Biological Products, (No Diagnostic Substances)
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections. Its drug development pipeline targets conditions such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. Key drug candidates in development include pevifoscorvir sodium for chronic HBV infection, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections. The company’s potential customers and end users include patients suffering from viral infections and liver disorders, as well as collaboration and licensing partners such as Xiamen Amoytop Biotech Co., Ltd.
Company profile, executives and historyAligos Therapeutics stock: common questions
What is Aligos Therapeutics's stock price?
ALGS closed at $2.16 on Nov 11, 2026, down 15.95% on the day. Over the past 52 weeks it traded between $2.02 and $13.69.
What is Aligos Therapeutics's market cap?
Aligos Therapeutics was worth $26.98M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ALGS's P/E ratio?
Aligos Therapeutics lost money over fiscal 2025 (diluted EPS -$2.45), so it has no meaningful P/E ratio.
How much revenue does Aligos Therapeutics make?
Aligos Therapeutics reported revenue of $5.83M for the twelve months to Sep 30, 2026, up 122.2% from a year earlier.
Does Aligos Therapeutics pay a dividend?
No. Aligos Therapeutics has not paid a cash dividend over the last twelve months.
When does Aligos Therapeutics report earnings next?
Aligos Therapeutics is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ALGS stock performed over the past year?
Including dividends, ALGS returned -67.7% over the past year, against +12.4% for the S&P 500.
Who are Aligos Therapeutics's competitors?
Companies most similar to Aligos Therapeutics by business, industry and size include PRME, TSHA, OCGN, ELOX, MOLN.
See a number that looks wrong?